Corvus Pharmaceuticals Inc (CRVS)

Corvus Pharmaceuticals Inc stock is traded at $10.57, with a volume of 1,272,220. It is up +7.53% in the last 24 hours and down -3.03% over the past month. Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.